INVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Innoviva Inc (INVA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and strategic growth initiatives, including a $125 million share repurchase program, make it a compelling investment opportunity. While technical indicators are neutral, the long-term growth potential outweighs short-term technical concerns.
The MACD is negatively expanding (-0.215), RSI is neutral at 35.311, and moving averages are converging. Key support is at $22.192, and resistance is at $24.618. Overall, technical indicators are neutral, with no strong buy or sell signals.
$125 million share repurchase program, reflecting confidence in growth.
Specialty Therapeutics sales expected to grow from $120 million to $150 million this year.
Strategic healthcare assets valued at over $600 million.
Analysts have raised price targets, with a high target of $46 and consistent 'Buy' ratings.
Gross margin dropped by 22.42% YoY in Q4
Technical indicators are neutral, with no clear upward momentum in the short term.
In Q4 2025, revenue increased by 24.84% YoY to $114.6M. Net income surged by 707.36% YoY to $164.15M. EPS grew by 822.73% YoY to $2.03. However, gross margin declined by 22.42% YoY to 66.02%. Overall, financial performance is strong, with significant growth in revenue, net income, and EPS.
Analysts are bullish on INVA. Cantor Fitzgerald raised the price target to $32, citing strong revenue growth and potential royalties. BTIG initiated coverage with a Buy rating and a $35 price target, highlighting royalty potential and diversified growth. H.C. Wainwright raised the price target to $46, citing successful drug approvals and growth catalysts.
